Home » Agenda » Day 2 – Friday 17th February 2023

Day 2 – Friday 17th February 2023

CHALLENGES & POTENTIALS OF PATIENT ENGAGEMENT

  • Why diversity and inclusion in clinical trials are crucial?
  • Understanding critical barriers to minority and underserved patient communities participation in clinical trials
  • Actionable ways to improve diversity in clinical trials
  • What can the industry do to promote more diversity in the future?
  • Latest guidelines that make healthcare more inclusive

Panellist:

Tricia Mullins, Global Head, Patient Advocacy, Atara Biotherapeutics

Teonna Woolford, Chief Executive Officer, Sickle Cell Reproductive Health Education Directive

  • How knowledge can reduce the fear of Pharma and ultimately save lives.
  • What do we really know about patient safety, both as an industry and an individual and what are the challenges we face?
  • How can technology play a role in ensuring patient safety, compliance and pharmacovigilance?
  • How we can leverage individual and collective data to ensure proper care and Quality of life while reducing damage, saving time and money.

Panelist

Christine Von Raesfeld, Founder & CEO, People with Empathy

Kristof Vanfraechem, Founder & CEO, Data For Patients

Carolina Consuegra, Co-Founder, Marketing & Strategy Director, Science2People

  • Support different learning styles to ensure patients have equal access to education
  • Patient centricity for better health outcomes
  • How to determine cultural nuances and understandings to care

Paula Orandash, Patient Engagement Liaison, PTC Therapeutics

  • Incorporating robust and meaningful patient engagement for a more informed decision-making
  • Strategies and best practices in facilitating patient recruitment and retention in clinical trials
  • Enhance understanding and use appropriate methods to capture patient understanding of the benefits and risk outcomes
  • How to best communicate patient information to support decision-making
  • What are logistical and financial challenges which increasingly impact all clinical trial stakeholders
  • Tailored approaches to travel services for the patients
  • Innovative reimbursement programmes
  • How to ensure patient safety and reliability

 

  • The importance of real-world patient data democratization
  • Common challenges in clinical data that hinders clinical trials
  • Strategies in overcoming these challenges
  • How to seamlessly integrate real-world data from a variety of sources?
  • Understanding complexities and addressing challenges faced by the industry in setting up end-to end supply chain for
    cell and gene therapies
  • Best practices and lessons learned that guarantees effective manufacturing and delivery of CGTs to the patients who
    needs them the most
  • Robust technologies and innovative platforms that connects therapies with patients both in clinical and commercial scale

ROUND TABLE DISCUSSIONS                 

14:00- 14:30, 14:35 – 15:05

Divided between 2 sessions of 30 mins. (5 mins. to change table) – Attendees have 2 round table options to attend

  • Recognising key areas to ensure patients’ experiences, perspectives, needs, and priorities are captured and meaningfully
    incorporated into drug development and evaluation.
  • Patient’s input to improve quality, relevance, safety and efficacy of drug development
  • Challenges and opportunities for patient-centric product design
  • The role of respective stakeholders and the way they interact, from the early steps of drug development to access in real
    life?

Panelists:
Juliette Chen, Global Evidence and Outcomes Leader, Takeda
Frank Rivera, President, Stronger Than Sarcoidosis

  • Learn how medical PTSD impacts patients ranging from newly diagnosed to long-term care
  • Understand the category of ways medical PTSD can develop
  • Discover opportunities for patients and providers to collaborate to alleviate symptoms of medical PTSD

Emily Parks, Founder, POP! Pissed Off Patients

  • Putting the patient first achieves the best experience and outcome for that person and their family
  • Improve communication from staff shift-changes in a hospital to getting the patient discharged faster
  • Setting expectations soon
  • Updating goals and outcomes; timely

Barby Ingle, President, International Pain Foundation

  • COVID-19 pandemic has highlighted the need for patient-centricity, understanding the drivers for innovation in pharma
  • Partnering with patients and placing patient well-being at the core of all initiatives
  • Shifting towards disease-oriented to patient-centric
  • Innovative approaches for direct-to-patient assume significant importance for driving patient-centricity
  • Technologies that enhance the patient-centricity in pharma
Scroll to Top